Clinical trial · Observational
Ablation of Hepatocellular Carcinoma: a Nationwide Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Chronic infection with hepatitis C virus (HCV) is a significant risk factor and may be associated with inferior outcome. According to the Danish national guidelines, ablation should be offered patients with early HCC (tumor \< 3 cm) in a cirrhotic liver, who are not transplant candidates. However, the effect of size of the HCC tumor and Hepatitis C virus (HCV) as etiology are insufficiently investigated. Purposes 1. Investigate association between HCC tumor size and survival and recurrence after ablation. 2. Investigate survival and recurrence after ablation in patients with HCV-related HCC compared with HCC due to other etiologies. Methods This study is based on data from the Danish Liver and Bile Duct Cancer Database (DLGCD) and the Danish Database for Hepatitis B and C (DANHEP) and the laboratory database (DANVIR), which collectively include information on patient characteristics, tumor characteristic, laboratory results, and information regarding ablation, HCV status, and antiviral treatment, respectively. Perspectives Ablation has been widely used for decades, but studies investigating the effect of ablation for HCC in patients with HCV and size of HCC are lacking. This study will contribute considerably to the level of evidence and may impact both Danish and international guidelines for HCC treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ablation | — | UNRESOLVED | — |
| Hepatitis C | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablation therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Non-resectable hepatocellular carcinoma
- description
- Patients treated with ablation therapy as first treatment for non-resectable hepatocellular carcinoma.
- interventionNames
- Procedure: Ablation therapy
Primary outcomes (2)
- measure
- Overall survival related to tumor size
- timeFrame
- January 2013 through August 2022
- description
- Overall survival will be estimated by Kaplan-Meier methods with log-rank tests, and Cox proportional hazards regression model
- measure
- Recurrence after ablation
- timeFrame
- January 2013 through August 2022
- description
- Recurrence by Aalen-Johansen estimator and Fine-Gray proportional subhazards model, death and transplantation as competing risks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma * Age \> 18 years * Ablation as the first surgical treatment for HCC Exclusion Criteria: * Hepatic resection or transplantation prior to ablation * Ablation performed in conjunction with resection * Ablation for recurrence of HCC
References
Publications (1)
- DERIVEDKlubien J, Knofler LA, Larsen PN, Tschuor C, Pless T, Gadsboll E, Kazlas L, Knudsen AR, Nielsen SD, Pommergaard HC. Nationwide study on survival and recurrence of hepatocellular carcinoma after ablation as first treatment. Surg Oncol. 2026 Apr;65:102391. doi: 10.1016/j.suronc.2026.102391. Epub 2026 Feb 26. PMID 41764872